Gender-Related Differences in Heart Failure Biomarkers

Area of Science:

• Cardiology
• Biomarkers
• Gender Medicine

Background:

• Significant differences in comorbidities and clinical profiles exist between men and women with heart failure (HF).
• Circulating biomarkers are crucial in cardiovascular care, yet sex-specific differences in their kinetics are often overlooked.
• Current clinical practice frequently assesses HF biomarkers without accounting for gender, despite observed variations in plasma concentrations.

Purpose of the Study:

• To review current evidence on gender-related differences in circulating biomarkers used in HF.
• To explore the pathophysiological mechanisms underlying these sex-specific biomarker variations.
• To discuss the clinical relevance and implications of these differences in HF management.

Main Methods:

• Literature review of studies examining sex differences in HF biomarkers.
• Analysis of pathophysiological factors contributing to observed gender-based variations.
• Evaluation of the clinical relevance of these differences for diagnosis and prognosis.

Main Results:

• Women and men with HF exhibit distinct patterns in biomarker levels: women generally have higher natriuretic peptides and galectin-3, and lower cardiac troponins and soluble ST2 compared to men.
• Biological factors such as body composition, fat distribution, and menopausal status contribute to these sex-specific differences.
• Observed biomarker differences do not necessarily imply divergent HF pathobiology or necessitate different diagnostic cut-offs.

Conclusions:

• Sex-specific differences in HF biomarkers are influenced by biological factors but do not reflect fundamentally different disease mechanisms.
• The prognostic value of HF biomarkers for risk stratification requires further investigation concerning sex-specific effects.
• Understanding these gender-related biomarker variations is essential for refining HF care and future research.